Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nazol is a topical nasal decongestant brand, most commonly formulated with oxymetazoline hydrochloride as its active pharmaceutical ingredient. As a sympathomimetic small molecule, oxymetazoline acts as an agonist at both alpha-1 and alpha-2 adrenergic receptors located within the smooth muscles of the nasal mucosal vasculature. Stimulation of these receptors induces local vasoconstriction of dilated arterioles, which reduces blood flow and edema in the nasal passages, thereby providing rapid relief from congestion. Nazol is indicated for the symptomatic treatment of acute rhinitis, sinusitis, and nasal congestion associated with the common cold, influenza, and allergic reactions. While the standard formulation focuses on oxymetazoline, variants like Nazol Advance include aromatic additives such as menthol, camphor, and eucalyptol to provide a cooling sensation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Nazol.